cohortId,atlasId,name,fullName
5357,5357,Canagliflozin,new users of canagliflozin
5361,5361,CanagliflozinCv,new users of canagliflozin with established cardiovascular disease
5363,5363,Empagliflozin,new users of empagliflozin
5364,5364,EmpagliflozinCv,new users of empagliflozin with established cardiovascular disease
5365,5365,Dapagliflozin,new users of dapagliflozin
5366,5366,DapagliflozinCv,new users of dapagliflozin with established cardiovascular disease
5367,5367,EmpagliflozinOrDapagliflozin,new users of empagliflozin or dapagliflozin
5368,5368,EmpagliflozinOrDapagliflozinCv,new users of empagliflozin or dapagliflozin with established cardiovascular disease
5369,5369,Ahas,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5370,5370,AhasCv,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease "
5371,5371,AhasWithInsulin,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA"
5372,5372,AhasWithInsulinCv,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease"
5373,5373,CanagliflozinAtLeast1PriorNonMetforminAha,new users of canagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure
5374,5374,CanagliflozinNoPriorNonMetforminAha,new users of canagliflozin with no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure
5375,5375,CanagliflozinNoPriorEmpagliflozin,new users of canagliflozin with no prior exposure to empagliflozin
5376,5376,CanagliflozinNoPriorDapagliflozin,new users of canagliflozin with no prior exposure to dapagliflozin
5377,5377,CanagliflozinNoPriorEmpagliflozinOrDapagliflozin,new users of canagliflozin with no prior exposure to empagliflozin or dapagliflozin
5378,5378,CanagliflozinNoPriorAhas,"new users of canagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5379,5379,CanagliflozinNoPriorAhasWithInsulin,"new users of canagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA"
5380,5380,CanagliflozinCvAtLeast1PriorNonMetforminAha,new users of canagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure
5381,5381,CanagliflozinCvNoPriorNonMetforminAha,new users of canagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first canagliflozin exposure
5382,5382,CanagliflozinCvNoPriorEmpagliflozin,new users of canagliflozin with established cardiovascular disease and no prior exposure to empagliflozin
5383,5383,CanagliflozinCvNoPriorDapagliflozin,new users of canagliflozin with established cardiovascular disease and no prior exposure to dapagliflozin
5384,5384,CanagliflozinCvNoPriorEmpagliflozinOrDapagliflozin,new users of canagliflozin with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin
5385,5385,CanagliflozinCvNoPriorAhas,"new users of canagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5386,5386,CanagliflozinCvNoPriorAhasWithInsulin,"new users of canagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA"
5387,5387,EmpagliflozinAtLeast1PriorNonMetforminAha,new users of empagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure
5388,5388,EmpagliflozinNoPriorNonMetforminAha,new users of empagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure
5389,5389,EmpagliflozinNoPriorCanagliflozin,new users of empagliflozin with no prior exposure to canagliflozin
5391,5391,EmpagliflozinCvAtLeast1PriorNonMetforminAha,new users of empagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure
5392,5392,EmpagliflozinCvNoPriorNonMetforminAha,new users of empagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin exposure
5393,5393,EmpagliflozinCvNoPriorCanagliflozin,new users of empagliflozin with established cardiovascular disease and no prior exposure to canagliflozin
5394,5394,DapagliflozinAtLeast1PriorNonMetforminAha,new users of dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure
5395,5395,DapagliflozinNoPriorNonMetforminAha,new users of dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure
5396,5396,DapagliflozinNoPriorCanagliflozin,new users of dapagliflozin with no prior exposure to canagliflozin
5397,5397,DapagliflozinCvAtLeast1PriorNonMetforminAha,new users of dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure
5398,5398,DapagliflozinCvNoPriorNonMetforminAha,new users of dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first dapagliflozin exposure
5399,5399,DapagliflozinCvNoPriorCanagliflozin,new users of dapagliflozin with established cardiovascular disease and no prior exposure to canagliflozin
5400,5400,EmpagliflozinOrDapagliflozinAtLeast1PriorNonMetforminAha,new users of empagliflozin or dapagliflozin with at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure
5401,5401,EmpagliflozinOrDapagliflozinNoPriorNonMetforminAha,new users of empagliflozin or dapagliflozin with no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure
5402,5402,EmpagliflozinOrDapagliflozinNoPriorCanagliflozin,new users of empagliflozin or dapagliflozin with no prior exposure to canagliflozin
5403,5403,EmpagliflozinOrDapagliflozinNoPriorAhas,"new users of empagliflozin or dapagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5404,5404,EmpagliflozinOrDapagliflozinNoPriorAhasWithInsulin,"new users of empagliflozin or dapagliflozin with no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA"
5405,5405,EmpagliflozinOrDapagliflozinCvAtLeast1PriorNonMetforminAha,new users of empagliflozin or dapagliflozin with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure
5406,5406,EmpagliflozinOrDapagliflozinCvNoPriorNonMetforminAha,new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first empagliflozin or dapagliflozin exposure
5407,5407,EmpagliflozinOrDapagliflozinCvNoPriorCanagliflozin,new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to canagliflozin
5408,5408,EmpagliflozinOrDapagliflozinCvNoPriorAhas,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5409,5409,EmpagliflozinOrDapagliflozinCvNoPriorAhasWithInsulin,"new users of empagliflozin or dapagliflozin with established cardiovascular disease and no prior exposure to any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA"
5410,5410,AhasAtLeast1PriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5411,5411,AhasNoPriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5412,5412,AhasNoPriorCanagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior exposure to canagliflozin"
5413,5413,AhasNoPriorEmpagliflozinOrDapagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with no prior exposure to empagliflozin or dapagliflozin"
5414,5414,AhasCvAtLeast1PriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5415,5415,AhasCvNoPriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA"
5417,5417,AhasCvNoPriorEmpagliflozinOrDapagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin"
5418,5418,AhasWithInsulinAtLeast1PriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA "
5419,5419,AhasWithInsulinNoPriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA "
5420,5420,AhasWithInsulinNoPriorCanagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior exposure to canagliflozin"
5421,5421,AhasWithInsulinNoPriorEmpagliflozinOrDapagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with no prior exposure to empagliflozin or dapagliflozin"
5422,5422,AhasWithInsulinCvAtLeast1PriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and at least 1 prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA "
5426,5426,AhasWithInsulinCvNoPriorNonMetforminAha,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior non-metformin AHA exposure in 365 days prior to first exposure of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA "
5429,5429,AhasWithInsulinCvNoPriorCanagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior exposure to canagliflozin"
5430,5430,AhasWithInsulinCvNoPriorEmpagliflozinOrDapagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, TZD, SU, insulin, or other select AHA with established cardiovascular disease and no prior exposure to empagliflozin or dapagliflozin"
5431,5431,AhasCvNoPriorCanagliflozin,"new users of any DPP-4 inhibitor, GLP-1 agonist, or other select AHA with established cardiovascular disease and no prior exposure to canagliflozin"
5432,5432,HeartFailure,hospitalizations for heart failure (primary inpatient diagnosis)
5433,5433,BkleAmputation,Below Knee Lower Extremity Amputation events
